Erectile dysfunction and heart blood supply in men treated for high blood pressure
Compares a heart blood-flow measure in treated hypertensive men with and without erectile dysfunction.
Plain-language title generated from the registry record
Registry title: Does Erectile Dysfonction Allow to Evaluate Subendocardial Viability Among Treated Patients With Hypertension ?
Key facts
- Where
- Paris, FranceSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men aged 18 or older who have hypertension and take blood pressure medicine. They must have no known heart disease. The study compares men with and without erectile dysfunction.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Confirmed hypertension, with no history of cardiovascular disease and no symptoms of coronary artery disease
- Earlier treatment
- Must be taking medicine for hypertension
Main reasons for not taking part
- Permanent atrial fibrillation
- Recurrent cardiac arrhythmias
- Not affiliated with a French social security scheme
- Opposition to taking part
Read by machine on 12 November 2026.
Where in France
- Hôpital LariboisièreParis, FranceContact: Guy AMAH, MDNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Trial code
- NCT07719790
- Record updated
- 22 July 2026
- Original description
Erectile dysfunction (ED) is associated with subclinical atherosclerosis and may precede clinically apparent coronary artery disease by two to five years. It may therefore serve as an early warning sign of cardiovascular disease and help identify patients who could benefit from intensified cardiovascular risk-factor management. The subendocardial viability ratio (SEVR), also known as the Buckberg index, is obtained noninvasively from radial artery applanation tonometry. SEVR reflects the balance between myocardial oxygen supply and demand and has been associated with coronary flow reserve in patients with hypertension. The DEVISE study will compare SEVR between treated men with hypertension who have ED with those who do not. The study will also examine the associations between ED severity and arterial stiffness, central hemodynamics, exercise capacity, left ventricular mass, coronary artery calcium, high-sensitivity C-reactive protein, cardiovascular risk, and quality of life.Read full original descriptionShow less
Does Erectile Dysfonction is Correlated to Subendocardial Viability Among Treated Patients With Hypertension ?
Erectile dysfunction (ED) is associated with subclinical atherosclerosis and may precede clinically apparent coronary artery disease by two to five years. It may therefore serve as an early warning sign of cardiovascular disease and help identify patients who could benefit from intensified cardiovascular risk-factor management. The subendocardial viability ratio (SEVR), also known as the Buckberg index, is obtained noninvasively from radial artery applanation tonometry. SEVR reflects the balance between myocardial oxygen supply and demand and has been associated with coronary flow reserve in patients with hypertension. The DEVISE study will compare SEVR between treated men with hypertension who have ED with those who do not. The study will also examine the associations between ED severity and arterial stiffness, central hemodynamics, exercise capacity, left ventricular mass, coronary artery calcium, high-sensitivity C-reactive protein, cardiovascular risk, and quality of life.
The question addressed in our study is whether an alteration in subendocardial viability represents subclinical coronary disease associated with ED.
Inclusion: Male participant aged 18 years or older; Confirmed diagnosis of hypertension; Receiving pharmacological antihypertensive treatment; Consecutively admitted to the hypertension day-hospital unit for assessment of hypertension-mediated organ damage; No history of cardiovascular disease, particularly coronary artery disease, and asymptomatic for coronary artery disease; Affiliated with a French social security scheme; Having received the study information and not expressed opposition to participating.
Exclusion: Recurrent cardiac arrhythmias; Permanent atrial fibrillation; Not affiliated with a French social security scheme; Opposition to participation.